vs
Side-by-side financial comparison of TRANSACT TECHNOLOGIES INC (TACT) and TriSalus Life Sciences, Inc. (TLSI). Click either name above to swap in a different company.
TriSalus Life Sciences, Inc. is the larger business by last-quarter revenue ($13.2M vs $11.5M, roughly 1.2× TRANSACT TECHNOLOGIES INC). On growth, TriSalus Life Sciences, Inc. posted the faster year-over-year revenue change (59.8% vs 11.9%). TRANSACT TECHNOLOGIES INC produced more free cash flow last quarter ($589.0K vs $-2.5M). Over the past eight quarters, TriSalus Life Sciences, Inc.'s revenue compounded faster (43.0% CAGR vs 3.5%).
Roper Technologies, Inc. is a holding company that owns companies in the technology sector.
TriSalus Life Sciences, Inc. is a clinical-stage biotechnology company focused on advancing immuno-oncology and interventional oncology solutions. It develops proprietary targeted drug delivery technologies designed to improve treatment efficacy for patients with liver, pancreatic and other hard-to-treat solid tumors, primarily operating in North American markets via partnerships with clinical care and research institutions.
TACT vs TLSI — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $11.5M | $13.2M |
| Net Profit | — | $-9.8M |
| Gross Margin | 47.6% | 86.7% |
| Operating Margin | -10.1% | -24.8% |
| Net Margin | — | -73.9% |
| Revenue YoY | 11.9% | 59.8% |
| Net Profit YoY | — | 3.5% |
| EPS (diluted) | $-0.11 | $-0.22 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $11.5M | $13.2M | ||
| Q3 25 | $13.2M | $11.6M | ||
| Q2 25 | $13.8M | $11.2M | ||
| Q1 25 | $13.1M | $9.2M | ||
| Q4 24 | $10.2M | $8.3M | ||
| Q3 24 | $10.9M | $7.3M | ||
| Q2 24 | $11.6M | $7.4M | ||
| Q1 24 | $10.7M | $6.5M |
| Q4 25 | — | $-9.8M | ||
| Q3 25 | $15.0K | $-10.8M | ||
| Q2 25 | $-143.0K | $-8.3M | ||
| Q1 25 | $19.0K | $-10.4M | ||
| Q4 24 | — | $-10.1M | ||
| Q3 24 | $-551.0K | $-2.4M | ||
| Q2 24 | $-319.0K | $-4.3M | ||
| Q1 24 | $-1.0M | $-13.2M |
| Q4 25 | 47.6% | 86.7% | ||
| Q3 25 | 49.8% | 83.5% | ||
| Q2 25 | 48.2% | 83.9% | ||
| Q1 25 | 48.7% | 83.7% | ||
| Q4 24 | 44.2% | 85.3% | ||
| Q3 24 | 48.1% | 86.3% | ||
| Q2 24 | 52.7% | 87.6% | ||
| Q1 24 | 52.6% | 85.0% |
| Q4 25 | -10.1% | -24.8% | ||
| Q3 25 | 0.1% | -77.9% | ||
| Q2 25 | -1.9% | -65.4% | ||
| Q1 25 | -0.1% | -79.9% | ||
| Q4 24 | -10.3% | -91.8% | ||
| Q3 24 | -7.7% | -118.9% | ||
| Q2 24 | -3.8% | -111.0% | ||
| Q1 24 | -12.2% | -180.8% |
| Q4 25 | — | -73.9% | ||
| Q3 25 | 0.1% | -93.5% | ||
| Q2 25 | -1.0% | -73.9% | ||
| Q1 25 | 0.1% | -113.2% | ||
| Q4 24 | — | -122.4% | ||
| Q3 24 | -5.1% | -32.6% | ||
| Q2 24 | -2.8% | -58.8% | ||
| Q1 24 | -9.7% | -204.5% |
| Q4 25 | $-0.11 | $-0.22 | ||
| Q3 25 | $0.00 | $-0.96 | ||
| Q2 25 | $-0.01 | $-0.27 | ||
| Q1 25 | $0.00 | $-0.39 | ||
| Q4 24 | $-0.80 | $-0.38 | ||
| Q3 24 | $-0.06 | $-0.12 | ||
| Q2 24 | $-0.03 | $-0.21 | ||
| Q1 24 | $-0.10 | $-0.60 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $20.4M | $20.4M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $31.1M | $-33.9M |
| Total Assets | $44.8M | $35.3M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $20.4M | $20.4M | ||
| Q3 25 | $20.0M | $22.7M | ||
| Q2 25 | $17.7M | $26.5M | ||
| Q1 25 | $14.2M | $13.0M | ||
| Q4 24 | $14.4M | $8.5M | ||
| Q3 24 | $11.3M | $11.3M | ||
| Q2 24 | $11.1M | $16.5M | ||
| Q1 24 | $10.6M | $4.0M |
| Q4 25 | $31.1M | $-33.9M | ||
| Q3 25 | $31.8M | $-26.7M | ||
| Q2 25 | $31.3M | $-19.4M | ||
| Q1 25 | $30.9M | $-34.4M | ||
| Q4 24 | $30.6M | $-25.9M | ||
| Q3 24 | $38.4M | $-20.4M | ||
| Q2 24 | $38.5M | $-25.3M | ||
| Q1 24 | $38.6M | $-36.0M |
| Q4 25 | $44.8M | $35.3M | ||
| Q3 25 | $45.0M | $36.5M | ||
| Q2 25 | $44.5M | $41.3M | ||
| Q1 25 | $44.2M | $28.6M | ||
| Q4 24 | $44.0M | $24.0M | ||
| Q3 24 | $50.5M | $27.5M | ||
| Q2 24 | $50.4M | $32.4M | ||
| Q1 24 | $51.9M | $17.9M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $609.0K | $-2.5M |
| Free Cash FlowOCF − Capex | $589.0K | $-2.5M |
| FCF MarginFCF / Revenue | 5.1% | -19.1% |
| Capex IntensityCapex / Revenue | 0.2% | 0.3% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $7.6M | $-19.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $609.0K | $-2.5M | ||
| Q3 25 | $3.6M | $-3.7M | ||
| Q2 25 | $3.6M | $-7.3M | ||
| Q1 25 | $-161.0K | $-4.5M | ||
| Q4 24 | $2.4M | $-5.7M | ||
| Q3 24 | $327.0K | $-10.8M | ||
| Q2 24 | $636.0K | $-13.4M | ||
| Q1 24 | $-1.5M | $-10.9M |
| Q4 25 | $589.0K | $-2.5M | ||
| Q3 25 | $3.6M | $-3.9M | ||
| Q2 25 | $3.6M | $-7.4M | ||
| Q1 25 | $-171.0K | $-5.3M | ||
| Q4 24 | $2.4M | $-5.8M | ||
| Q3 24 | $259.0K | $-11.0M | ||
| Q2 24 | $499.0K | $-13.5M | ||
| Q1 24 | $-1.6M | $-10.9M |
| Q4 25 | 5.1% | -19.1% | ||
| Q3 25 | 27.1% | -33.9% | ||
| Q2 25 | 25.9% | -66.1% | ||
| Q1 25 | -1.3% | -57.3% | ||
| Q4 24 | 23.2% | -69.7% | ||
| Q3 24 | 2.4% | -149.9% | ||
| Q2 24 | 4.3% | -183.1% | ||
| Q1 24 | -14.9% | -169.3% |
| Q4 25 | 0.2% | 0.3% | ||
| Q3 25 | 0.5% | 1.9% | ||
| Q2 25 | 0.1% | 0.8% | ||
| Q1 25 | 0.1% | 8.2% | ||
| Q4 24 | 0.1% | 0.6% | ||
| Q3 24 | 0.6% | 2.3% | ||
| Q2 24 | 1.2% | 0.8% | ||
| Q1 24 | 1.0% | 1.0% |
| Q4 25 | — | — | ||
| Q3 25 | 242.00× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | -8.47× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
